secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K/A
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001558370-25-000053
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro discloses Zoetis MFA portfolio audited financials: $407.6M revenue in FY2023
--------------------------------------------------------------------------------

- Acquired MFA portfolio had $407.6M revenue & $91.2M revenue less direct expenses in 2023; up from $59.9M in 2022.
- Cost of sales was $284.3M in 2023 vs $310.3M in 2022; gross margin improved to 30.3% from 23.9%.
- Total assets acquired as of Dec 2023: $334M; liabilities assumed: $24.5M; net assets ~$309.5M.
- Transaction closed Oct 31, 2024 for $350M subject to adjustments; includes six manufacturing plants.
- Pro forma financials filed for year ended June 30, 2024; combined entity impact not yet quantified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837025000053/0001558370-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837025000053/pahc-20241031x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer